Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.
Cambridge: AstraZeneca has announced that its New Drug Application (NDA) for baxdrostat has been accepted for Priority Review ...
AstraZeneca’s NDA for baxdrostat accepted under US FDA Priority Review in US for patients with hard-to-control hypertension: Cambridge, UK Wednesday, December 3, 2025, 09:00 Hrs ...
Chronic kidney disease (CKD) is on the rise in the United States, with roughly 36 million adults estimated to have the ...
Drugs like gabapentin and pregabalin are known to cause fluid retention, leading to symptoms that doctors can confuse for ...
A surprising link between constipation and kidney decline led researchers to test lubiprostone, revealing that it can protect ...
A rare and life-threatening kidney disease in children finally has an effective therapy, thanks in large part to pioneering ...
MannKind Corporation beats Q3 estimates and sees FDA progress on ReadyFlow Autoinjector, presenting strong revenue growth potential. Learn more about MNKD stock here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback